Global Medicare · Ovarian Science
Understanding ovarian reserve, ovarian response and the IVF context.
Explore the scientific framework used to understand ovarian-factor fertility concerns and the parameters observed within the ExoRegenOvo research program at IVF Baden-Baden.
Scientific information on this page is educational. Individual AMH, AFC, ultrasound or IVF findings require interpretation by an authorised medical professional.
Core ovarian concepts
Ovarian reserve and ovarian response are related — but not identical.
They form part of the clinical information used by fertility specialists when assessing ovarian-factor fertility concerns and planning IVF or ICSI care.
Ovarian reserve
Ovarian reserve refers to the available follicular pool considered within the broader reproductive and clinical context. Measures such as AMH and antral follicle count may form part of specialist assessment, but they should not be interpreted in isolation.
Ovarian response
Ovarian response describes how the ovaries respond during controlled stimulation in an IVF or ICSI cycle. Previous stimulation history and laboratory outcomes can therefore provide clinically relevant information for specialist assessment.
Global Medicare does not classify individual AMH, AFC or stimulation results as “good” or “bad”. Clinical interpretation belongs to the medical team.
Clinical context
Ovarian-factor fertility is not defined by a single number.
Age, previous ovarian response, ovarian-reserve information and the broader reproductive history can all contribute to an individual specialist assessment.
Prospective observation
The research follows outcomes across a treatment sequence.
02-REGEN-AR prospectively compares the total number of transferable embryos obtained during a sequence of up to three stimulation cycles.
The number of cycles performed depends on the individual clinical course. The study documents outcomes rather than assigning the treatment approach.
Clinical and IVF laboratory outcomes are documented prospectively.
Outcomes are considered cumulatively within the treatment sequence.
A third cycle may occur according to the clinical course; PRP/IAS is not administered during the third retrieval.
The primary research endpoint is the total number of transferable embryos obtained by the end of the treatment sequence.
What is observed?
Multiple parameters help describe the clinical picture.
The observational framework includes IVF laboratory, ovarian and reproductive parameters collected during routine clinical care.
Ovarian reserve-related parameters recorded within the clinical context.
Laboratory information includes the number of mature MII oocytes.
Embryo number, transferable embryos and embryo quality are documented.
Pregnancy, live-birth and follow-up information may be documented where applicable.
These parameters are research and clinical data points. They should not be used online to calculate individual prognosis or predict treatment success.
Autologous preparations
Standard-PRP and IAS are two distinct preparation approaches.
Both approaches are autologous and use material obtained from the patient’s own blood.
IAS includes additional processing steps designed to recover and recombine naturally occurring components from fractions of the same autologous sample.
The clinical choice between Standard-PRP and IAS is made before and independently of research participation.
IAS should not be presented as purified exosome therapy or as clinically superior to Standard-PRP.
ExoRegenOvo
Study 02-REGEN-AR02-REGEN-AR is a prospective, observational, single-centre and non-randomised study conducted at IVF Baden-Baden under the direction of Prof. Dr. med. Wolfgang Küpker.
The planned sample is 104 participants: 52 Standard-PRP and 52 IAS.
Scientific interpretation
Observational data require careful interpretation.
The design of 02-REGEN-AR is prospective and observational, not randomised. The research documents outcomes associated with clinical care rather than assigning treatment.
AMH, AFC, previous IVF response or age cannot be converted by this website into an individual treatment prognosis.
The study compares outcomes between Standard-PRP and IAS but does not justify presenting one approach as clinically superior in public communication.
Participation in observational research does not guarantee improved ovarian reserve, more embryos, pregnancy or live birth.
Continue exploring
Science provides context. Specialist evaluation applies it to the individual case.
If your situation involves low ovarian reserve, poor ovarian response, previous IVF or age-related ovarian factors, explore the Ovarian Program for the patient pathway or continue to the research study.